The Feline Hepatic UGT Defect and Cannabinoid Metabolism: A Comparative Pharmacokinetic Analysis

By Will Scott | Published October 21, 2026

A cat’s response to a medicine begins within a biological inheritance that predates the domestic animal by millions of years. Among its defining features is the loss of functional UGT1A6, an enzyme involved in the conjugation of particular compounds, carried within a liver that retains numerous other routes of chemical transformation.^[1][2][3] Cannabinoids enter this selective metabolic landscape as individual molecules, each presenting a different set of possible reactions. Cannabidiol, or CBD, and cannabidiolic acid, or CBDA, have now been measured directly in feline circulation, alongside selected products of their metabolism.^[23][26] Those measurements bring the discussion closer to the living cat: the preparation swallowed, the meal accompanying it, the concentration reached and the compounds remaining after repeated administration. Food and formulation have emerged as consequential influences on exposure, while the responsible feline enzyme pathways remain less completely resolved.^[24][25][26] Understanding how these findings fit together requires following the molecule through the animal, keeping inherited conjugation capacity, absorption, oxidative metabolism and clinical response within the same account.

The Evolutionary Origin of the Feline UGT1A6 Defect

Glucuronidation transfers glucuronic acid to a suitable chemical group on a substrate, creating a conjugate whose subsequent disposition depends on its particular properties. The reaction is performed by a family of UDP-glucuronosyltransferases, with different members recognizing different substrates and attachment sites.^[1][6] Within that family, feline UGT1A6 contains disruptive mutations that prevent production of the normal functional enzyme. Molecular investigation also identified other expressed hepatic UGT1A sequences, establishing the coexistence of a specific genetic loss and retained conjugating machinery.^[2] The distinction has practical importance because the phrase “feline glucuronidation” encompasses many separate reactions. Some are markedly restricted; others remain readily measurable. A healthy cat carries this inherited arrangement throughout life, independently of whether it later develops an illness affecting the liver.^[1][6] The biological question therefore begins with the substrate: which reaction does it require, and which functioning enzyme can perform that reaction in this species?

Sequencing across felids placed the founding UGT1A6 disruption deep in their shared ancestry. The analysis identified common lesions across sampled species and inferred an ancestral fixation interval of approximately 36.5 to 10.8 million years ago, followed by additional mutations within particular lineages.^[3] Hypercarnivory offered a plausible evolutionary setting. Reduced exposure to some plant-derived compounds may have relaxed the pressure to retain an enzyme involved in their metabolism, permitting damaging mutations to persist. The authors treated diet as a proposed influence within an evolutionary process, supported by associations rather than a demonstrated single cause. Some hypercarnivorous relatives retained intact coding sequences, an important feature of the comparative evidence.^[3] What survives from that history is a selective enzyme repertoire, shaped by ancestry but encountered today through individual chemical reactions. Its significance for a cannabinoid depends on the pathway used by that cannabinoid, a question that can be addressed through direct metabolism studies rather than botanical origin alone.^[6][29]

What Acetaminophen Revealed About Catalytic Capacity

Acetaminophen research supplied a foundation for this substrate-centered approach by resolving the kinetics of a reaction known to be weak in feline liver. Comparative microsomal experiments identified high-affinity and low-affinity components of acetaminophen glucuronidation, with an especially low maximal velocity for the feline high-affinity component.^[4] Its mean maximal velocity was 0.025 nmol/min/mg microsomal protein, compared with 0.92 in dogs and 0.27 in humans. The feline affinity estimate fell within the comparative range, placing the most conspicuous difference in apparent catalytic capacity. These results helped explain limited acetaminophen conjugation through a measurable reaction characteristic, while the amount of responsible enzyme protein remained an inference from kinetic behavior rather than a direct protein measurement.^[4] A companion investigation examined microsomal enzyme constraint by testing detergent activation. Increasing access within the preparation did not eliminate the feline deficit, narrowing the explanation beyond a general problem of reaction accessibility.^[5] The studies are enduring examples of how a species difference becomes mechanistically useful: the substrate is specified, the reaction is isolated and competing explanations are tested against experimental behavior.

That precision also establishes the scope of the acetaminophen findings. Their relevance to cannabinoid research lies in the investigative method and the known limits of the feline enzyme repertoire. CBD, CBDA and their metabolites each require their own pathway assignments. Their structures offer possible sites for transformation, but the importance of any site depends on recognition by available enzymes and on the rates of competing reactions.^[6][29] A cannabinoid concentration curve adds further influences, including absorption and distribution, which lie outside the isolated acetaminophen reaction.^[24][25] Connecting a particular feline UGT to CBD clearance would therefore require evidence linking that enzyme to the relevant cannabinoid reaction, followed by an assessment of how much the reaction contributes within the animal. The genetic lesion identifies an important feature of the system; substrate experiments establish where that feature matters.

The Conjugation Pathways Cats Retain

A broader panel of glucuronidation substrates made the selectivity of feline metabolism visible. Liver microsomes showed low activity toward several reactions, including morphine-3-glucuronide formation, alongside retained activity toward others. Estradiol provided a particularly instructive comparison because conjugation differed according to the position receiving glucuronic acid.^[6] The molecule’s name alone could not describe that distinction. Telmisartan extended the evidence in another direction: feline liver microsomes readily formed its acyl glucuronide, which was also detected in plasma from treated cats.^[7] The study established a functioning reaction without resolving the responsible feline isoform. Together, these experiments show why enzyme-family labels are only a starting point. Effective conjugation depends on a compatible pairing of substrate and enzyme, and the capacity observed with one pairing does not quantify another.^[6][7] For CBD and CBDA, the relevant task is to identify those pairings and determine their contribution alongside oxidative pathways.

Mycophenolic acid illustrates how several conjugation routes can share the handling of one substrate. In feline microsomes, weak phenol glucuronidation occurred alongside retained acyl glucuronidation and substantial phenol glucosidation, with the glucose conjugate accounting for approximately 60 percent of total feline conjugation in the experiment.^[8] Glucose conjugation and glucuronic acid conjugation produce different chemical products, despite the similarity of their names. The alternative route narrowed the deficit in overall conjugation, although total predicted conjugation clearance remained lower in cats than in the comparative canine and human systems. This is metabolic flexibility with a measurable extent, rather than complete compensation.^[8] The distinction matters whenever a pathway is described as a substitute for another: its actual contribution must be measured for the substrate under study. A parent compound may encounter multiple reactions, and the products formed provide evidence about how those reactions divide the metabolic work.

Botanical substrates reinforce that chemical specificity. Soy isoflavones yielded different urinary glucuronide fractions in cats, with genistein, daidzein and glycitein following different patterns; comparative dietary exposure and sampling also differed between the studied species.^[9] In the resveratrol investigation, the targeted glucuronides were undetected under the sampled conditions while a sulfate conjugate was identified, documenting another substrate-specific disposition profile.^[10] These observations make accurate reaction terminology essential. UGTs form glucuronides, whereas beta-glucuronidase hydrolyzes them, so the formation and breakdown of a conjugate represent different biochemical steps.^[1][9] Work on O-desmethyltramadol adds a useful analytical distinction: a small feline glucuronide product was detectable even when substrate depletion did not permit a robust quantitative clearance estimate under the tested conditions.^[11] Product detection and parent disappearance therefore contribute different information. Following both is especially valuable when activity is limited, because a reaction can be present without producing enough depletion for a reliable rate estimate.

The Feline Oxidative Enzyme Landscape

Conjugation sits within a wider system of biotransformation whose oxidative machinery is distributed across tissues. A feline transcriptomic investigation identified 42 CYP transcripts across 20 tissues, substantially broadening the described cytochrome P450 repertoire.^[12] Transcripts establish gene expression; protein abundance and substrate activity occupy subsequent experimental layers. Targeted research placed CYP3A131 prominently in liver and small intestine, with much lower CYP3A132 expression detected in liver.^[13] Broader RNA sequencing produced a different apparent balance between these related transcripts, with annotation and mapping overlap considered as possible explanations.^[12] Such differences are consequential when assigning a pathway, because an abundant sequence signal and an abundant functioning enzyme are not interchangeable observations. The combined evidence supports investigation of both intestinal and hepatic metabolism while preserving the need to determine which proteins actually process a cannabinoid and at what rate.

Other CYP families reveal equally important features of the feline inventory. Research on CYP2C identified a CYP2C21 pseudogene and limited expression of a functional CYP2C41 variant; among the splice variants examined, only one encoded a complete functional form.^[14] Functional feline CYP2B6 was characterized in a different anatomical setting, with expression concentrated in lung and some intestinal expression, while substantial hepatic expression was not demonstrated under the study conditions.^[15] CYP2D6 showed prominent hepatic transcripts, creating another distinct distribution within the same animal.^[16] These findings give tissue location a central place in pharmacokinetic interpretation. The presence of an enzyme somewhere in the body establishes neither its abundance in liver nor its contribution to hepatic clearance. Direct microsomal characterization, including research on selected CYP-associated probe activities, supplies functional information that complements this expression map.^[20] For cannabinoid metabolism, expression and activity become most useful when measured together with the actual substrate.

Variation within the feline population adds another dimension. Studies of CYP3A, CYP1A2 and CYP2A identified genetic variants associated with different activities toward selected probes in recombinant systems.^[17][18][19] A clinical investigation of clopidogrel also found substantial variation in active-metabolite concentrations, with associations involving sex and a CYP2C polymorphism.^[21] This gives individual metabolic biology an experimentally grounded place in the discussion of feline drug exposure. CBD studies likewise report considerable variation between cats, although their concentration differences can include absorption, administration and other influences alongside metabolism.^[24][25] Identifying a cannabinoid-specific genetic association would require linking the variant to the relevant reaction and then to exposure in living cats. Until that connection is established, variability is best examined as a set of possible contributions rather than assigned wholesale to one enzyme.

Oral CBD Exposure Begins Before Hepatic Clearance

An oral dose enters a sequence that includes ingestion, release from the formulation, intestinal uptake, presystemic loss, distribution and elimination. The concentration measured in blood reflects their combined behavior.^[24][25] Cmax describes the highest observed concentration, Tmax records when it occurred, and AUC summarizes exposure across a defined interval. Apparent oral clearance, expressed as CL/F, includes the unknown bioavailable fraction, so a change in that estimate can arise from changes in delivery to the circulation as well as systemic elimination.^[25] This becomes particularly important when comparing formulations. An early feline investigation used a hemp preparation containing CBD and CBDA, while later work examined CBD isolate; the amount of CBD itself must be distinguished from combined cannabinoid content before comparing their results.^[23][24] The preparation is part of the exposure, not a detail separable from it. A meaningful comparison carries the analyte, administered amount, vehicle and collection schedule alongside the reported number.

The escalating single-dose isolate study found that exposure increased approximately in proportion to dose across its studied range, despite substantial individual variability.^[24] That finding characterizes oral disposition under an intermittent research protocol with washouts. Food introduced a different and particularly strong influence in the study of a purified CBD medication, where the mean increase in relative bioavailability was approximately 10.8-fold in the fed condition.^[25] The figure arose from individual dose-adjusted AUC comparisons and belongs to the medication and conditions tested. Its significance is that feeding can alter the amount reaching circulation sufficiently to dominate a comparison that might otherwise be explained through liver metabolism. Actual ingestion also matters: incomplete consumption changes the delivered dose before the concentration curve begins.^[25] For research interpretation and patient observation alike, meal context and the quantity swallowed are therefore essential companions to the nominal milligrams offered.

Numerical comparisons require attention to the interval and the calculation as well. A four-hour AUC covers a different period from a twenty-four-hour AUC, and a mean of individual exposure ratios need not equal a ratio calculated from two group means.^[25][27] The mathematical summary is shaped by the study design. Terminal half-life estimates are similarly dependent on the measurable portion of the curve, the sampling schedule and the data available for fitting its final slope.^[24] Different feline studies have produced different estimates using different formulations and protocols, giving those estimates a context rather than making one value a permanent species constant.^[24][26] Interpreting the curve as a record of a particular administration preserves what it can genuinely explain. It also makes apparent disagreements more useful, turning them into questions about formulation, uptake and study design that a controlled comparison can investigate.

CBDA and the Metabolic Trail Beyond CBD

The CBD/CBDA-rich paste study widened the feline pharmacokinetic picture by following an acidic cannabinoid alongside CBD and selected metabolites. CBDA reached higher serum concentrations than CBD under the tested conditions, producing a distinct exposure profile within the same administered preparation.^[26] The two compounds had their own administered amounts and their own disposition, so their curves are best read individually before considering the mixture. The investigation also detected 7-carboxy-CBD in all studied cats, establishing a measurable product of CBD biotransformation in feline circulation.^[26] That product adds a second temporal story to the parent curve: formation introduces it into circulation, while its distribution and elimination influence how long it remains measurable. Measuring both compounds helps reveal how exposure changes across repeated administrations. It also extends the research beyond the assumption that disappearance of parent CBD alone captures the entire metabolic process.

Repeated dosing brings those overlapping processes into sharper focus. The paste investigation sampled cats after multiple administrations, while a separate controlled feeding study compared exposure after the initial administration with exposure after two weeks and found higher measured CBD exposure at the later assessment.^[26][27] Each observation belongs to its stated collection schedule. A sample obtained several hours after a dose describes that point in the interval; an AUC calculated over four hours describes those four hours. Complete profiles across successive intervals would provide a fuller account of parent persistence and metabolite behavior. The available findings establish that repeated exposure can differ from the first administration, while their explanation remains connected to the processes determining oral disposition.^[25][27] Assigning the change to a particular enzyme would require evidence at that additional mechanistic level.

The analytical panel determines how much of this trail becomes visible. A metabolite below the quantification threshold has not yielded a reliable numerical value within that assay, specimen and sampling window; products outside the panel are outside the experiment’s measured account.^[26][28] Serum detection also addresses a different question from recovery of the administered dose through excretion. A comprehensive mass-balance study would follow parent compounds and products leaving the body, allowing the circulation profile to be connected with final routes of removal. The distinction is fundamental: biotransformation changes a molecule, while elimination describes its departure from the body.^[1] Combining detailed metabolite measurements with recovery studies would help identify which reactions contribute most to overall disposition and which steps govern persistence. The existing feline serum studies establish important portions of that account, including exposure to parent cannabinoids and a confirmed CBD metabolite.^[23][26]

Interactions Depend on the Pathway and the Preparation

Feline interaction experiments show how laboratory findings can be connected to disposition in the animal. Ketoconazole inhibited selected CYP3A-associated reactions in feline microsomes and reduced quinidine clearance in the in vivo component of the study. Cimetidine produced laboratory inhibition without the same clearance effect in living cats.^[22] The comparison places achievable inhibitor exposure, substrate behavior and experimental conditions at the center of interaction assessment. Cannabinoid-specific mechanistic work has explored related questions in canine material, where CBD depletion depended on oxidative cofactors and CBDA depletion depended on the glucuronidation cofactor, with evidence supporting an acyl glucuronide.^[29] Selected tramadol reactions were also inhibited. These results identify reactions in the canine test system and supply concrete hypotheses for feline experiments. Determining their relevance in cats requires accounting for the feline enzyme inventory, including differences in functional CYP2C expression and the tissue distribution of other enzymes.^[14][15][29]

Composition introduces another source of variation before concurrent prescriptions are considered. The feline escalating-dose tolerability investigation used oils with different cannabinoid profiles and carriers, administered intermittently rather than as continuous daily treatment.^[28] Higher concentrations associated with a combination preparation suggested an interaction, but the formulations also differed in cannabinoid amounts and vehicle. The most defensible interpretation therefore remains attached to the individual analytes, collection times and preparations. Tolerability followed a similarly informative pattern: THC-containing oils were associated more often with neurological and behavioral signs, while gastrointestinal events clustered predominantly with MCT formulations, including placebo.^[28] Those observations make the carrier part of the pharmacological account. A characterized preparation provides the information needed to investigate an effect; a broad label such as “full spectrum” or “isolate” cannot by itself describe the exposure, interaction potential or source of an adverse event.

Relating Exposure to the Cat’s Clinical Experience

Longer administration studies contribute a different kind of evidence from a single-dose concentration curve. The early hemp investigation reported a persistent ALT elevation in one cat, while a later controlled feeding program followed healthy cats receiving daily CBD with food over substantially longer periods.^[23][27] The latter supported tolerability under its defined conditions and used an equivalence framework for clinical chemistry. Those results belong to the studied population, formulation and duration. ALT contributes to evaluation of the animal, whereas cannabinoid concentrations describe exposure to the measured compounds; their interpretation remains complementary rather than interchangeable.^[1][27] An enzyme-specific explanation requires additional evidence beyond either result. Considering clinical observations, chemistry and administration history together gives changes their appropriate context and allows a veterinarian to investigate the individual patient without forcing every finding into a predetermined metabolic explanation.

Clinical benefit introduces the question that makes pharmacokinetics useful to care. Feline trials involving chronic gingivostomatitis, an acute transport-and-novel-person stress paradigm and osteoarthritic pain examined different outcomes with different preparations and populations.^[30][31][32] Their results inform those separate clinical questions. The gingivostomatitis study evaluated an adjunct within a multimodal protocol; the stress study found no significant effect on its measured responses; the osteoarthritis field study reported improvements among completers while experiencing substantial withdrawal.^[30][31][32] Refusal of the paste was an important practical issue in the latter investigation, showing how acceptance influences delivery before absorption can be assessed. The quantity offered and the quantity swallowed may differ. Recording that difference helps separate inadequate delivery from a pharmacological response and connects the analytical concentration with what actually happened in the cat’s daily care.^[32]

Healthy cats have supplied much of the foundational exposure evidence, leaving important questions for populations with gastrointestinal disease, altered hepatic function, concurrent treatment or inconsistent food intake.^{[23][24][25][27]} Extending research into those settings would make the existing pharmacokinetic findings more useful to complex patients. A well-defined exposure-response relationship would then connect a reproducible concentration profile with a meaningful outcome and an acceptable tolerability profile for a particular indication.^[24][30][32] That is a more clinically valuable destination than choosing the preparation that produces the largest reported blood concentration. The objective is to understand which exposure serves the animal, how reliably it can be delivered and what changes when the animal’s condition changes.

A More Complete Account of Feline Cannabinoid Disposition

The next advances can build directly on the separate layers already established. Feline substrate experiments can assign reactions to functional proteins; repeated-dose studies can follow parent compounds and metabolites across complete intervals; recovery studies can connect those circulating profiles with final routes of elimination.^[6][12][26] Route comparisons would help separate oral bioavailability from systemic clearance, while controlled formulation comparisons would reduce the uncertainty introduced by differences between cohorts and feeding protocols.^[24][25] Clinical studies could then examine whether defined exposures track outcomes in the patient population of interest. Each experimental layer resolves a different part of the same journey. Bringing them together would replace a concentration curve interpreted in isolation with a fuller account of delivery, transformation, persistence and response.

The feline UGT1A6 defect remains a landmark in that account, embedded within a liver whose retained conjugation pathways and oxidative repertoire are demonstrably selective.^[2][6][12] Direct CBD and CBDA studies have already added food effects, formulation-dependent exposure, circulating metabolites and changes during repeated administration to the picture.^[25][26][27] Comparative pharmacology is most valuable when these details sharpen the view of the cat itself. Its inherited biology defines the system; the administered molecule reveals which parts of that system matter. Following both with equal care gives cannabinoid research a sounder foundation for the clinical questions still ahead.